Farmaceutico inglese
L’energy crunch decreta due grandi vincitori: settore oil e azionario Russia
I mercati hanno ripreso vigore nella prima parte di ottobre dopo il settembre incolore con Wall Street e Borse UE. Tra i settori a fare la voce grossa spicca ancora …
Enel si risveglia dal letargo, per il peso massimo di Piazza Affari sponda da rumor in Spagna. Analisti vedono upside di almeno il 25%
Ulteriore accelerazione a Piazza Affari per il titolo Enel che arriva a segnare oltre +2% in area 7,05 euro. A dare slancio all'utility guidata da Francesco Starace sono le notizie …
Squid Game effect anche a Wall Street, riflettori su Netflix. Attese per 3° trimestre e analisi tecnica del titolo
La tornata di trimestrali di Wall Street in arrivo nei prossimi giorni vede in primo piano i numeri di Netflix che alzerà il velo sui conti oggi a mercati chiusi. …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #1
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0

    Farmaceutico inglese

    23.07.2008 - MILANO (Finanza.com)
    Il gruppo farmaceutico inglese GlaxoSmithKline mostra una trimestrale in salute. Il secondo trimestre si è chiuso con un utile netto in rialzo del 13% a 1,446 miliardi di sterline, con un utile per azione di 27,2 pence contro i 24 pence del corrispondente periodo del 2007. Il fatturato è salito del 4% a 5,87 miliardi di sterline.


  2. #2

    Data Registrazione
    Nov 2006
    Messaggi
    14,759
    Mentioned
    116 Post(s)
    Quoted
    6734 Post(s)
    Potenza rep
    42934646
    Stavo seguendo anche io, desideroso di entrare anche nel settore chimico-farmaceutico. Purtroppo non so valutare i multipli del settore ed il P/E a 14 non mi sembrava molto basso.

  3. #3
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Citazione Originariamente Scritto da Lupak Visualizza Messaggio
    Stavo seguendo anche io, desideroso di entrare anche nel settore chimico-farmaceutico. Purtroppo non so valutare i multipli del settore ed il P/E a 14 non mi sembrava molto basso.
    Certo, ma a mio giudizio, Glaxosmithkline è un gruppo internazionale farmaceutico che, assieme a Sanofi-Aventis, Pfizer e Merck & Co, non può mancare in un portafoglio ben diversificato nel settore farma...

    I dividendi sono trimestrali (in alternativa al reinvestimento in azioni...) e attualmente sommano a circa 55 pence... (4,5%)
    Ultima modifica di shark2007; 20-11-10 alle 21:53

  4. #4

    Data Registrazione
    Feb 2008
    Messaggi
    19,013
    Mentioned
    0 Post(s)
    Quoted
    1288 Post(s)
    Potenza rep
    0
    Tue Nov 16, 2010 7:48pm GMT

    ADELPHI, Maryland - Advisers are considering whether to recommend approval of a highly anticipated lupus treatment from Human Genome Sciences Inc amid concerns the drug might increase suicides or carry other serious risks.

    Benlysta could be the first medicine in a half-century to win approval for fighting the debilitating and potentially fatal autoimmune disease. Annual global sales are forecast at $2.2 billion by 2014, according to Thomson Reuters.

    That would transform unprofitable biotech Human Genome into an industry star.

    The company would split Benlysta profits with partner GlaxoSmithKline Plc.

    A Food and Drug Administration advisory panel, set to vote later on Tuesday, heard pitches from Human Genome and patients who pushed for the medicine's approval. But FDA reviewers questioned how much benefit the drug offered and noted potential risks.

    Human Genome argued the intravenous drug was an important advance for fighting lupus, a disease that causes the immune system to attack the body's own tissue and organs. That can lead to arthritis, kidney damage, chest pain, fatigue, skin rash and other problems. Organ damage can be fatal, and current treatments have severe side effects.

    Lupus patients have "persevered through a decade of failed trials," said Dr. Michelle Petri, a rheumatologist at Johns Hopkins University and consultant to Human Genome. Benlysta offers "compelling efficacy" with a "favorable safety profile," she told the panel.

    Forty-six-year-old Donna Flenory said lupus caused severe fatigue and joint pain that forced her to give up her career as an occupational therapist. High doses of steroids improved her symptoms for a time but repeated flare-ups sent her to the hospital every year, usually in the autumn.

    After joining a study of Benlysta, "when fall rolled around I was no longer sick. I had a life again," she told the panel, adding "please realize we as patients need something."

    FDA reviewers, however, suggested Benlysta might have only a modest effect on lupus symptoms and might raise the risk of death, infection, or psychiatric problems including suicide. Two patients treated with Benlysta during clinical trials killed themselves and there were no suicides with a placebo.

    ANALYSTS PREDICT APPROVAL

    Industry analysts said ahead of the meeting that they expected the advisory panel to endorse the drug and the FDA to ultimately approve it for sale. Many said lupus patients already faced serious health problems, and there was no clear evidence Benlysta contributed to deaths or suicides.

    ...


    U.S. advisers back Human Genome lupus drug | Reuters

  5. #5
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Citazione Originariamente Scritto da asqueldaz Visualizza Messaggio
    Tue Nov 16, 2010 7:48pm GMT

    ADELPHI, Maryland - Advisers are considering whether to recommend approval of a highly anticipated lupus treatment from Human Genome Sciences Inc amid concerns the drug might increase suicides or carry other serious risks.

    Benlysta could be the first medicine in a half-century to win approval for fighting the debilitating and potentially fatal autoimmune disease. Annual global sales are forecast at $2.2 billion by 2014, according to Thomson Reuters.

    That would transform unprofitable biotech Human Genome into an industry star.

    The company would split Benlysta profits with partner GlaxoSmithKline Plc.

    A Food and Drug Administration advisory panel, set to vote later on Tuesday, heard pitches from Human Genome and patients who pushed for the medicine's approval. But FDA reviewers questioned how much benefit the drug offered and noted potential risks.

    Human Genome argued the intravenous drug was an important advance for fighting lupus, a disease that causes the immune system to attack the body's own tissue and organs. That can lead to arthritis, kidney damage, chest pain, fatigue, skin rash and other problems. Organ damage can be fatal, and current treatments have severe side effects.

    Lupus patients have "persevered through a decade of failed trials," said Dr. Michelle Petri, a rheumatologist at Johns Hopkins University and consultant to Human Genome. Benlysta offers "compelling efficacy" with a "favorable safety profile," she told the panel.

    Forty-six-year-old Donna Flenory said lupus caused severe fatigue and joint pain that forced her to give up her career as an occupational therapist. High doses of steroids improved her symptoms for a time but repeated flare-ups sent her to the hospital every year, usually in the autumn.

    After joining a study of Benlysta, "when fall rolled around I was no longer sick. I had a life again," she told the panel, adding "please realize we as patients need something."

    FDA reviewers, however, suggested Benlysta might have only a modest effect on lupus symptoms and might raise the risk of death, infection, or psychiatric problems including suicide. Two patients treated with Benlysta during clinical trials killed themselves and there were no suicides with a placebo.

    ANALYSTS PREDICT APPROVAL

    Industry analysts said ahead of the meeting that they expected the advisory panel to endorse the drug and the FDA to ultimately approve it for sale. Many said lupus patients already faced serious health problems, and there was no clear evidence Benlysta contributed to deaths or suicides.

    ...


    U.S. advisers back Human Genome lupus drug | Reuters

  6. #6
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Citazione Originariamente Scritto da shark2007 Visualizza Messaggio
    Certo, ma a mio giudizio, Glaxosmithkline è un gruppo internazionale farmaceutico che, assieme a Sanofi-Aventis, Pfizer e Merck & Co, non può mancare in un portafoglio ben diversificato nel settore farma...

    I dividendi sono trimestrali (in alternativa al reinvestimento in azioni...) e attualmente sommano a circa 55 pence... (4,5%)
    Confermo tutto il mio vecchio post e ... preciso che ora il dividendo totale annuale di Glaxosmithkline è salito a 65 pence ... !
    Ultima modifica di shark2007; 04-02-11 alle 19:21

  7. #7
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    03.02.2011 - MILANO (Finanza.com)

    Trimestrale debole per GlaxoSmithKline.
    Il gruppo farmaceutico inglese ha chiuso il quarto trimestre del 2010 con un rosso di 690 milioni di sterline da un utile di 1,63 miliardi di sterline dello stesso periodo del 2009.
    Il gruppo ha deciso di alzare il dividendo annuale a 65 pence.
    La società ha anche annunciato un piano di buy back di 1-2 miliardi di sterline da attuare nel corso del 2011.


    Le perdite del Q4 2010 sono dovute a costi straordinari di ristrutturazione.
    Titolo sugli scudi a Londra ...
    Ultima modifica di shark2007; 04-02-11 alle 19:15

  8. #8
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Thursday, 3rd February 2011, London, UK

    Unaudited Preliminary Results Announcement for the year ended 31st December 2010

    Strategic progress drives positive underlying sales growth* increasing pipeline potential and improved cash generation.

    Increased dividend and new long-term share buy-back programme enhance returns to shareholders.




    Prox dividendo trimestrale di Aprile 2011 fissato a 19 pence ... !
    Ultima modifica di shark2007; 04-02-11 alle 19:13

  9. #9
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Titolo sempre sugli scudi a Londra ... !

  10. #10
    L'avatar di shark2007
    Data Registrazione
    Oct 2007
    Messaggi
    50,185
    Mentioned
    18 Post(s)
    Quoted
    7554 Post(s)
    Potenza rep
    0
    Titolo attorno alle 12 £ ...

Accedi